BioSpace News Archive

Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax’’ or the ''Company’’), an outcome-driven connected healthcare company, today announced its wholly owned subsidiary Parallax Diagnostics, Inc. will execute a partnership strategy to develop, acquire or license monoclonal and polyclonal antibodies for the creation of a low cost and rapid screening test for COVID-19

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the acceptance for presentation of its abstract of the results for Cohort 1 from its Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously treated non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations.

Neuromod Devices Limited (“Neuromod” or “The Company”), the Irish medical technology company specialising in non-invasive neuromodulation technologies, is pleased to announce that Mr. Florian Elsaesser has been appointed as Chief Commercial Officer.

Brii Biosciences (“Brii Bio”) and Columbia University have entered into a memorandum of understanding through which Brii Bio will provide funding to support research to be conducted by investigators at the university and led by David Ho, M.D., founding scientific director of the Aaron Diamond AIDS Research Center and professor of medicine at the Vagelos College of Physicians and Surgeons

Oncology Pharma, Inc. (OTCPK: ONPH) is pleased to announce that it is continuing its relationship with NanoSmart Pharmaceuticals, Inc. and has extended its Licensing Agreement and co-development for both its human oncology and veterinary oncology pharmaceuticals for another year

IBM Watson Health (NYSE: IBM) and EBSCO Information Services (EBSCO) today announced a strategic collaboration aimed towards enhancing clinical decision support (CDS) and operations for healthcare providers and health systems

Biocare Medical (“Biocare”), a leading developer of world class immunohistochemistry (“IHC”) and molecular reagents and instrumentation, is pleased to announce that Luis de Luzuriaga has joined the company as Chief Executive Officer.

Strand Therapeutics, an mRNA gene therapy company specialized in utilizing synthetic biology for immunotherapy of cancer, announced today the appointment of industry leaders, Dr. Dane Wittrup to its Scientific Advisory Board and Dr. Mark Frohlich to its newly formed Clinical Advisory Board.

Creative Medical Technology Holdings announced today, what appears to be, the first personalized adoptive immunotherapy for treatment of autoimmunity, which the Company named “IMMCELZ™"

ForteBio announced that to aid in the discovery of human therapeutic antibodies to viral infections like dengue fever and eastern equine encephalitis, the Vanderbilt Vaccine Center recently became one of the first academic institutes in North America to adopt ForteBio’s Octet HTX system.